SHIELD THERAPEUTICS PLC (STX) — Q4 2025 Trading Update

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the SHIELD THERAPEUTICS PLC Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged, and they can be submitted at any time using the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question received during the meeting itself. However, company can review your questions submitted today and publish responses where it is appropriate to do so. Before we begin, I would like to submit the following poll. And I would now like to hand you over to Anders Lundstrom, CEO. Good afternoon to you, sir. Thank you so much, and good afternoon, good morning, depending where you are in the world. So welcome to SHIELD THERAPEUTICS trading update covering the fourth quarter and the full year of 2025. My name is, Anders Lustrom. I'm the CEO. And together with me this afternoon is also Santoshanberg, our CFO, and we will take you through the presentation, and then answer a lot of, of course, your questions when we come to the end. So this is our disclaimer. I leave it up for a little bit. And just so know, this presentation that we will be shared with you today will be available on our website, corporate website, in the next coming days. So SHIELD THERAPEUTICS, we are a specialty pharmaceutical company. We are focusing on the iron deficiency and iron deficiency anemia market. It's a very, very big global market. And in The US alone, there's about fourteen million iron deficient, patient diagnosed. Our product is called Aquifer or Feracru depending on where in the world you are. And what we offer these patients is a better tolerated product because the the the, problem sometimes wi...